New perspectives on the vitamin D binding protein

Cell Biochemistry and Function

Volumn 30, Issue 6, 2012, Pages 445-456

  Chun, Rene F ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

DBP; DBP MAF; Endocrinology; GC globulin; Immunology; Vitamin D

Indexed keywords

ACTIN; FATTY ACID; VITAMIN D; VITAMIN D BINDING PROTEIN;

ACTIN POLYMERIZATION; GENETIC VARIABILITY; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN LIPID INTERACTION; REVIEW; VITAMIN D METABOLISM;

ANIMALS; GENETIC VARIATION; HUMANS; VITAMIN D; VITAMIN D-BINDING PROTEIN;

EID: 84865382853     PISSN: 02636484     EISSN: 10990844     Source Type: Journal    
DOI: 10.1002/cbf.2835     Document Type: Review

References (172)

1. Holick MF. Vitamin D deficiency. N Engl J Med 2007; 357(3): 266-81.
2. Heaney RP. Long-latency deficiency disease: insights from calcium and vitamin D. Am J Clin Nutr 2003; 78(5): 912-9.
3. Priemel M, von Domarus C, Klatte TO, et al. Bone mineralization defects and vitamin D deficiency: histomorphometric analysis of iliac crest bone biopsies and circulating 25-hydroxyvitamin D in 675 patients. J Bone Miner Res 2010; 25(2): 305-12.
4. Feskanich D, Ma J, Fuchs CS, et al. Plasma vitamin D metabolites and risk of colorectal cancer in women. Cancer Epidemiol Biomarkers Prev 2004; 13(9): 1502-8.
5. Giovannucci E, Liu Y, Rimm EB, et al. Prospective study of predictors of vitamin D status and cancer incidence and mortality in men. J Natl Cancer Inst 2006; 98(7): 451-9.
6. Garland CF, Gorham ED, Mohr SB, Garland FC. Vitamin D for cancer prevention: global perspective. Ann Epidemiol 2009; 19(7): 468-83.
7. Munger KL, Zhang SM, O'Reilly E, et al. Vitamin D intake and incidence of multiple sclerosis. Neurology 2004; 62(1): 60-5.
8. Munger KL, Levin LI, Hollis BW, Howard NS, Ascherio A. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 2006; 296(23): 2832-8.
9. Ascherio A, Munger KL, Simon KC. Vitamin D and multiple sclerosis. Lancet Neurol 2010; 9(6): 599-612.
10. Krause R, Buhring M, Hopfenmuller W, Holick MF, Sharma AM. Ultraviolet B and blood pressure. Lancet 1998; 352(9129): 709-10.
11. Lee JH, O'Keefe JH, Bell D, Hensrud DD, Holick MF. Vitamin D deficiency an important, common, and easily treatable cardiovascular risk factor? J Am Coll Cardiol 2008; 52(24): 1949-56.
12. Wang TJ, Pencina MJ, Booth SL, et al. Vitamin D deficiency and risk of cardiovascular disease. Circulation 2008; 117(4): 503-11.
13. Hewison M. Antibacterial effects of vitamin D. Nat Rev Endocrinol 2011; 7(6): 337-45.
14. Leow L, Simpson T, Cursons R, Karalus N, Hancox RJ. Vitamin D, innate immunity and outcomes in community acquired pneumonia. Respirology 2011; 16(4): 611-6.
15. Martineau AR, Nhamoyebonde S, Oni T, et al. Reciprocal seasonal variation in vitamin D status and tuberculosis notifications in Cape Town, South Africa. Proc Natl Acad Sci U S A 2011; 108(47): 19013-7.
16. Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011; 96(7): 1911-30.
17. Ginde AA, Liu MC, Camargo CA, Jr. Demographic differences and trends of vitamin D insufficiency in the US population, 1988-2004. Arch Intern Med 2009; 169(6): 626-32.
18. Ross AC, Manson JE, Abrams SA, et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab 2011; 96(1): 53-8.
19. Haddad JG. Plasma vitamin D-binding protein (Gc-globulin): multiple tasks. J Steroid Biochem Mol Biol 1995; 53(1-6): 579-82.
20. White P, Cooke N. The multifunctional properties and characteristics of vitamin D-binding protein. Trends Endocrinol Metab 2000; 11(8): 320-7.
21. Speeckaert M, Huang G, Delanghe JR, Taes YE. Biological and clinical aspects of the vitamin D binding protein (Gc-globulin) and its polymorphism. Clin Chim Acta 2006; 372(1-2): 33-42.
22. Bouillon R. The vitamin D binding protein DBP. In Vitamin D (3rd edn.), Vol. 1, Feldman D, Pike JW, Adams JS (eds.). Academic Press: London, 2011; 57-72.
23. Hirschfeld J. Immune-electrophoretic demonstration of qualitative differences in human sera and their relation to the haptoglobins. Acta Pathol Microbiol Scand 1959; 47: 160-8.
24. Daiger SP, Schanfield MS, Cavalli-Sforza LL. Group-specific component (Gc) proteins bind vitamin D and 25-hydroxyvitamin D. Proc Natl Acad Sci U S A 1975; 72(6): 2076-80.
25. Jones G, Prosser DE. The activating enzymes of vitamin D metabolism (25- and 1a-hydroxylases). In Vitamin D (3rd edn.), Vol. 1, Feldman D, Pike JW, Adams JS (eds.). Academic Press: London, 2011; 23-42.
26. Cheng JB, Motola DL, Mangelsdorf DJ, Russell DW. De-orphanization of cytochrome P450 2R1: a microsomal vitamin D 25-hydroxilase. J Biol Chem 2003; 278(39): 38084-93.
27. Zehnder D, Bland R, Williams MC, et al. Extrarenal expression of 25-hydroxyvitamin d(3)-1 alpha-hydroxylase. J Clin Endocrinol Metab 2001; 86(2): 888-94.
28. St-Arnaud R. CYP24A1: structure, function, and physiological role. In Vitamin D (3rd edn.), Vol. 1, Feldman D, Pike JW, Adams JS (eds.). Academic Press: London, 2011; 43-56.
29. Haussler MR, Whitfield GK, Haussler CA, Hsieh J-C, Jurutka PW. Nuclear vitamin D receptor: natural ligands, molecular structure-function, and transcriptional control of vital genes. In Vitamin D (3rd edn.), Vol. 1, Feldman D, Pike JW, Adams JS (eds.). Academic Press: London, 2011; 137-170.
30. Meyer MB, Goetsch PD, Pike JW. Genome-wide analysis of the VDR/RXR cistrome in osteoblast cells provides new mechanistic insight into the actions of the vitamin D hormone. J Steroid Biochem Mol Biol 2010; 121(1-2): 136-41.
31. Heikkinen S, Vaisanen S, Pehkonen P, Seuter S, Benes V, Carlberg C. Nuclear hormone 1alpha, 25-dihydroxyvitamin D3 elicits a genome-wide shift in the locations of VDR chromatin occupancy. Nucleic Acids Res 2011; 39(21): 9181-93.
32. Pike JW. Genome-wide principles of gene regulation by the vitamin D receptor and its activating ligand. Mol Cell Endocrinol 2011; 347(1-2): 3-10.
33. Safadi FF, Thornton P, Magiera H, et al. Osteopathy and resistance to vitamin D toxicity in mice null for vitamin D binding protein. J Clin Invest 1999; 103(2): 239-51.
34. Haddad JG, Matsuoka LY, Hollis BW, Hu YZ, Wortsman J. Human plasma transport of vitamin D after its endogenous synthesis. J Clin Invest 1993; 91(6): 2552-5.
35. Kamboh MI, Ferrell RE. Ethnic variation in vitamin D-binding protein (GC): a review of isoelectric focusing studies in human populations. Hum Genet 1986; 72(4): 281-93.
36. Cooke NE, Walgate J, Haddad JG, Jr. Human serum binding protein for vitamin D and its metabolites. II. Specific, high affinity association with a protein in nucleated tissue. J Biol Chem 1979; 254(13): 5965-71.
37. Cooke NE, Walgate J, Haddad JG, Jr. Human serum binding protein for vitamin D and its metabolites. I. Physicochemical and immunological identification in human tissues. J Biol Chem 1979; 254(13): 5958-64.
38. Van Baelen H, Bouillon R, De Moor P. Vitamin D-binding protein (Gc-globulin) binds actin. J Biol Chem 1980; 255(6): 2270-2.
39. Haddad JG. Human serum binding protein for vitamin D and its metabolites (DBP): evidence that actin is the DBP binding component in human skeletal muscle. Arch Biochem Biophys 1982; 213(2): 538-44.
40. Cooke NE, Willard HF, David EV, George DL. Direct regional assignment of the gene for vitamin D binding protein (Gc-globulin) to human chromosome 4q11-q13 and identification of an associated DNA polymorphism. Hum Genet 1986; 73(3): 225-9.
41. Song YH, Naumova AK, Liebhaber SA, Cooke NE. Physical and meiotic mapping of the region of human chromosome 4q11-q13 encompassing the vitamin D binding protein DBP/Gc-globulin and albumin multigene cluster. Genome Res 1999; 9(6): 581-7.
42. Hiroki T, Song YH, Liebhaber SA, Cooke NE. The human vitamin D-binding protein gene contains locus control determinants sufficient for autonomous activation in hepatic chromatin. Nucleic Acids Res 2006; 34(8): 2154-65.
43. Song YH, Ray K, Liebhaber SA, Cooke NE. Vitamin D-binding protein gene transcription is regulated by the relative abundance of hepatocyte nuclear factors 1alpha and 1beta. J Biol Chem 1998; 273(43): 28408-18.
44. McLeod JF, Cooke NE. The vitamin D-binding protein, alpha-fetoprotein, albumin multigene family: detection of transcripts in multiple tissues. J Biol Chem 1989; 264(36): 21760-9.
45. Cooke NE, David EV. Serum vitamin D-binding protein is a third member of the albumin and alpha fetoprotein gene family. J Clin Invest 1985; 76(6): 2420-4.
46. Yang F, Brune JL, Naylor SL, Cupples RL, Naberhaus KH, Bowman BH. Human group-specific component (Gc) is a member of the albumin family. Proc Natl Acad Sci U S A 1985; 82(23): 7994-8.
47. Svasti J, Kurosky A, Bennett A, Bowman BH. Molecular basis for the three major forms of human serum vitamin D binding protein (group-specific component). Biochemistry 1979; 18(8): 1611-7.
48. Borges CR, Jarvis JW, Oran PE, Nelson RW. Population studies of Vitamin D Binding Protein microheterogeneity by mass spectrometry lead to characterization of its genotype-dependent O-glycosylation patterns. J Proteome Res 2008; 7(9): 4143-53.
49. Svasti J, Bowman BH. Human group-specific component. Changes in electrophoretic mobility resulting from vitamin D binding and from neuraminidase digestion. J Biol Chem 1978; 253(12): 4188-94.
50. Coppenhaver DH, Sollenne NP, Bowman BH. Post-translational heterogeneity of the human vitamin D-binding protein (group-specific component). Arch Biochem Biophys 1983; 226(1): 218-23.
51. Viau M, Constans J, Debray H, Montreuil J. Isolation and characterization of the O-glycan chain of the human vitamin-D binding protein. Biochem Biophys Res Commun 1983; 117(1): 324-31.
52. Ravnsborg T, Olsen DT, Thysen AH, Christiansen M, Houen G, Hojrup P. The glycosylation and characterization of the candidate Gc macrophage activating factor. Biochim Biophys Acta 2010; 1804(4): 909-17.
53. Bikle DD, Gee E, Halloran B, Kowalski MA, Ryzen E, Haddad JG. Assessment of the free fraction of 25-hydroxyvitamin D in serum and its regulation by albumin and the vitamin D-binding protein. J Clin Endocrinol Metab 1986; 63(4): 954-9.
54. Bikle DD, Siiteri PK, Ryzen E, Haddad JG. Serum protein binding of 1, 25-dihydroxyvitamin D: a reevaluation by direct measurement of free metabolite levels. J Clin Endocrinol Metab 1985; 61(5): 969-75.
55. Mc Leod JF, Kowalski MA, Haddad JG, Jr. Interactions among serum vitamin D binding protein, monomeric actin, profilin, and profilactin. J Biol Chem 1989; 264(2): 1260-7.
56. Calvo M, Ena JM. Relations between vitamin D and fatty acid binding properties of vitamin D-binding protein. Biochem Biophys Res Commun 1989; 163(1): 14-7.
57. Verboven CC, De Bondt HL, De Ranter C, Bouillon R, Van Baelen H. Crystallization and X-ray investigation of vitamin D-binding protein from human serum. Identification of the crystal content. J Steroid Biochem Mol Biol 1995; 54(1-2): 11-4.
58. Verboven C, Rabijns A, De Maeyer M, Van Baelen H, Bouillon R, De Ranter C. A structural basis for the unique binding features of the human vitamin D-binding protein. Nat Struct Biol 2002; 9(2): 131-6.
59. Rochel N, Wurtz JM, Mitschler A, Klaholz B, Moras D. The crystal structure of the nuclear receptor for vitamin D bound to its natural ligand. Mol Cell 2000; 5(1): 173-9.
60. Bogaerts I, Verboven C, Rabijns A, Waelkens E, Van Baelen H, De Ranter C. Purification, crystallization and preliminary X-ray investigation of the complex of human vitamin D binding protein and rabbit muscle actin. Acta Crystallogr D Biol Crystallogr 2001; 57(Pt 5): 740-2.
61. Otterbein LR, Cosio C, Graceffa P, Dominguez R. Crystal structures of the vitamin D-binding protein and its complex with actin: structural basis of the actin-scavenger system. Proc Natl Acad Sci U S A 2002; 99(12): 8003-8.
62. Verboven C, Bogaerts I, Waelkens E, et al. Actin-DBP: the perfect structural fit? Acta Crystallogr D Biol Crystallogr 2003; 59(Pt 2): 263-73.
63. Hay AW, Watson G. The plasma transport proteins of 25-hydroxycholecalciferol in mammals. Comp Biochem Physiol B 1976; 53(2): 163-6.
64. Van Baelen H, Allewaert K, Bouillon R. New aspects of the plasma carrier protein for 25-hydroxycholecalciferol in vertebrates. Ann N Y Acad Sci 1988; 538: 60-8.
65. Hay AW, Watson G. The plasma transport proteins of 25-hydroxycholecalciferol in fish, amphibians, reptiles and birds. Comp Biochem Physiol B 1976; 53(2): 167-72.
66. Allewaert K, Van Baelen H, Bouillon R. Vitamin D-binding protein in pisces. Steroids 1988; 52(4): 357-8.
67. NCBI BLASTP search query with human DBP (NP_000574.2) amino acids 26-206.
68. NCBI BLASTP search query with human DBP (NP_000574.2) amino acids 405-472.
69. Vieth R, Kessler MJ, Pritzker KP. Species differences in the binding kinetics of 25-hydroxyvitamin D3 to vitamin D binding protein. Can J Physiol Pharmacol 1990; 68(10): 1368-71.
70. Horst RL, Napoli JL, Littledike ET. Discrimination in the metabolism of orally dosed ergocalciferol and cholecalciferol by the pig, rat and chick. Biochem J 1982; 204(1): 185-9.
71. Armas LA, Hollis BW, Heaney RP. Vitamin D2 is much less effective than vitamin D3 in humans. J Clin Endocrinol Metab 2004; 89(11): 5387-91.
72. Houghton LA, Vieth R. The case against ergocalciferol (vitamin D2) as a vitamin supplement. Am J Clin Nutr 2006; 84(4): 694-7.
73. Constans J, Viau M. Group-specific component: evidence for two subtypes of the Gc1 gene. Science 1977; 198(4321): 1070-1.
74. Cleve H, Constans J. The mutants of the vitamin-D-binding protein: more than 120 variants of the GC/DBP system. Vox Sang 1988; 54(4): 215-25.
75. Constans J, Cleve H. Group-specific component. Report on the First International Workshop, College de France--July 27-28, 1978--Paris. Hum Genet 1979; 48(2): 143-9.
76. Arnaud J, Constans J. Affinity differences for vitamin D metabolites associated with the genetic isoforms of the human serum carrier protein (DBP). Hum Genet 1993; 92(2): 183-8.
77. Lauridsen AL, Vestergaard P, Nexo E. Mean serum concentration of vitamin D-binding protein (Gc globulin) is related to the Gc phenotype in women. Clin Chem 2001; 47(4): 753-6.
78. NCBI SNP database for GC, human. Available from http://www.ncbi.nlm.nih.gov/gene [13 January 2012].
79. Mourant AE, Tills D, Domaniewska-Sobczak K. Sunshine and the geographical distribution of the alleles of the Gc system of plasma proteins. Hum Genet 1976; 33(3): 307-14.
80. Vavrusa B, Cleve H, Constans J. A deficiency mutant of the Gc system. Hum Genet 1983; 65(2): 102-7.
81. White P, Liebhaber SA, Cooke NE. 129X1/SvJ mouse strain has a novel defect in inflammatory cell recruitment. J Immunol 2002; 168(2): 869-74.
82. Nykjaer A, Dragun D, Walther D, et al. An endocytic pathway essential for renal uptake and activation of the steroid 25-(OH) vitamin D3. Cell 1999; 96(4): 507-15.
83. Raychowdhury R, Niles JL, McCluskey RT, Smith JA. Autoimmune target in Heymann nephritis is a glycoprotein with homology to the LDL receptor. Science 1989; 244(4909): 1163-5.
84. Cui S, Verroust PJ, Moestrup SK, Christensen EI. Megalin/gp330 mediates uptake of albumin in renal proximal tubule. Am J Physiol 1996; 271(4 Pt 2): F900-7.
85. Kozyraki R, Fyfe J, Kristiansen M, et al. The intrinsic factor-vitamin B12 receptor, cubilin, is a high-affinity apolipoprotein A-I receptor facilitating endocytosis of high-density lipoprotein. Nat Med 1999; 5(6): 656-61.
86. Hammes A, Andreassen TK, Spoelgen R, et al. Role of endocytosis in cellular uptake of sex steroids. Cell 2005; 122(5): 751-62.
87. Marino M, Zheng G, Chiovato L, et al. Role of megalin (gp330) in transcytosis of thyroglobulin by thyroid cells. A novel function in the control of thyroid hormone release. J Biol Chem 2000; 275(10): 7125-37.
88. Nykjaer A, Fyfe JC, Kozyraki R, et al. Cubilin dysfunction causes abnormal metabolism of the steroid hormone 25(OH) vitamin D(3). Proc Natl Acad Sci U S A 2001; 98(24): 13895-900.
89. Christensen EI, Birn H. Megalin and cubilin: multifunctional endocytic receptors. Nat Rev Mol Cell Biol 2002; 3(4): 256-66.
90. Rowling MJ, Kemmis CM, Taffany DA, Welsh J. Megalin-mediated endocytosis of vitamin D binding protein correlates with 25-hydroxycholecalciferol actions in human mammary cells. J Nutr 2006; 136(11): 2754-9.
91. Atkins GJ, Anderson PH, Findlay DM, et al. Metabolism of vitamin D3 in human osteoblasts: evidence for autocrine and paracrine activities of 1 alpha, 25-dihydroxyvitamin D3. Bone 2007; 40(6): 1517-28.
92. Constans J, Oksman F, Viau M. Binding of the apo and holo forms of the serum vitamin D-binding protein to human lymphocyte cytoplasm and membrane by indirect immunofluorescence. Immunol Lett 1981; 3(3): 159-62.
93. Petrini M, Emerson DL, Galbraith RM. Linkage between surface immunoglobulin and cytoskeleton of B lymphocytes may involve Gc protein. Nature 1983; 306(5938): 73-4.
94. Esteban C, Geuskens M, Ena JM, et al. Receptor-mediated uptake and processing of vitamin D-binding protein in human B-lymphoid cells. J Biol Chem 1992; 267(14): 10177-83.
95. Zhang J, Habiel DM, Ramadass M, Kew RR. Identification of two distinct cell binding sequences in the vitamin D binding protein. Biochim Biophys Acta 2010; 1803(5): 623-9.
96. Chun RF, Lauridsen AL, Suon L, et al. Vitamin D-binding protein directs monocyte responses to 25-hydroxy- and 1, 25-dihydroxyvitamin D. J Clin Endocrinol Metab 2010; 95(7): 3368-76.
97. Zella LA, Shevde NK, Hollis BW, Cooke NE, Pike JW. Vitamin D-binding protein influences total circulating levels of 1, 25-dihydroxyvitamin D3 but does not directly modulate the bioactive levels of the hormone in vivo. Endocrinology 2008; 149(7): 3656-67.
98. Bikle DD, Gee E. Free, and not total, 1, 25-dihydroxyvitamin D regulates 25-hydroxyvitamin D metabolism by keratinocytes. Endocrinology 1989; 124(2): 649-54.
99. Liu PT, Stenger S, Li H, et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 2006; 311(5768): 1770-3.
100. Adams JS, Ren S, Liu PT, et al. Vitamin d-directed rheostatic regulation of monocyte antibacterial responses. J Immunol 2009; 182(7): 4289-95.
101. Dunn JF. Computer simulation of vitamin D transport. Ann N Y Acad Sci 1988; 538: 69-76.
102. Chun RF, Peercy BE, Adams JS, Hewison M. Vitamin D binding protein and monocyte response to 25-hydroxyvitamin D and 1, 25-dihydroxyvitamin D: analysis by mathematical modeling. PLoS One 2012; 7(1): e30773.
103. Powe CE, Ricciardi C, Berg AH, et al. Vitamin D-binding protein modifies the vitamin D-bone mineral density relationship. J Bone Miner Res 2011; 26(7): 1609-16.
104. Meier U, Gressner O, Lammert F, Gressner AM. Gc-globulin: roles in response to injury. Clin Chem 2006; 52(7): 1247-53.
105. Dahl B, Schiodt FV, Rudolph S, Ott P, Kiaer T, Heslet L. Trauma stimulates the synthesis of Gc-globulin. Intensive Care Med 2001; 27(2): 394-9.
106. Haddad JG, Harper KD, Guoth M, Pietra GG, Sanger JW. Angiopathic consequences of saturating the plasma scavenger system for actin. Proc Natl Acad Sci U S A 1990; 87(4): 1381-5.
107. Coue M, Constans J, Viau M, Olomucki A. The effect of serum vitamin D-binding protein on polymerization and depolymerization of actin is similar to the effect of profilin on actin. Biochim Biophys Acta 1983; 759(3): 137-45.
108. Lind SE, Smith DB, Janmey PA, Stossel TP. Role of plasma gelsolin and the vitamin D-binding protein in clearing actin from the circulation. J Clin Invest 1986; 78(3): 736-42.
109. Dueland S, Nenseter MS, Drevon CA. Uptake and degradation of filamentous actin and vitamin D-binding protein in the rat. Biochem J 1991; 274(Pt 1): 237-41.
110. Antoniades CG, Berry PA, Bruce M, et al. Actin-free Gc globulin: a rapidly assessed biomarker of organ dysfunction in acute liver failure and cirrhosis. Liver Transpl 2007; 13(9): 1254-61.
111. Schiodt FV, Bangert K, Shakil AO, et al. Predictive value of actin-free Gc-globulin in acute liver failure. Liver Transpl 2007; 13(9): 1324-9.
112. Gressner OA, Gao C, Siluschek M, Kim P, Gressner AM. Inverse association between serum concentrations of actin-free vitamin D-binding protein and the histopathological extent of fibrogenic liver disease or hepatocellular carcinoma. Eur J Gastroenterol Hepatol 2009; 21(9): 990-5.
113. Pihl TH, Jorgensen CS, Santoni-Rugiu E, et al. Safety Pharmacology, Toxicology and Pharmacokinetic Assessment of Human Gc Globulin (Vitamin D Binding Protein). Basic Clin Pharmacol Toxicol 2010; 107(5): 853-60.
114. Williams MH, Van Alstyne EL, Galbraith RM. Evidence of a novel association of unsaturated fatty acids with Gc (vitamin D-binding protein). Biochem Biophys Res Commun 1988; 153(3): 1019-24.
115. Swamy N, Ray R. Fatty acid-binding site environments of serum vitamin D-binding protein and albumin are different. Bioorg Chem 2008; 36(3): 165-8.
116. Bouillon R, Xiang DZ, Convents R, Van Baelen H. Polyunsaturated fatty acids decrease the apparent affinity of vitamin D metabolites for human vitamin D-binding protein. J Steroid Biochem Mol Biol 1992; 42(8): 855-61.
117. Spector AA. Fatty acid binding to plasma albumin. J Lipid Res 1975; 16(3): 165-79.
118. Ena JM, Esteban C, Perez MD, Uriel J, Calvo M. Fatty acids bound to vitamin D-binding protein (DBP) from human and bovine sera. Biochem Int 1989; 19(1): 1-7.
119. Watkins S, Madison J, Galliano M, Minchiotti L, Putnam FW. Analbuminemia: three cases resulting from different point mutations in the albumin gene. Proc Natl Acad Sci U S A 1994; 91(20): 9417-21.
120. Kew RR, Webster RO. Gc-globulin (vitamin D-binding protein) enhances the neutrophil chemotactic activity of C5a and C5a des Arg. J Clin Invest 1988; 82(1): 364-9.
121. Piquette CA, Robinson-Hill R, Webster RO. Human monocyte chemotaxis to complement-derived chemotaxins is enhanced by Gc-globulin. J Leukoc Biol 1994; 55(3): 349-54.
122. Binder R, Kress A, Kan G, Herrmann K, Kirschfink M. Neutrophil priming by cytokines and vitamin D binding protein (Gc-globulin): impact on C5a-mediated chemotaxis, degranulation and respiratory burst. Mol Immunol 1999; 36(13-14): 885-92.
123. Zhang J, Kew RR. Identification of a region in the vitamin D-binding protein that mediates its C5a chemotactic cofactor function. J Biol Chem 2004; 279(51): 53282-7.
124. Shah AB, DiMartino SJ, Trujillo G, Kew RR. Selective inhibition of the C5a chemotactic cofactor function of the vitamin D binding protein by 1, 25(OH)2 vitamin D3. Mol Immunol 2006; 43(8): 1109-15.
125. Nagasawa H, Uto Y, Sasaki H, et al. Gc protein (vitamin D-binding protein): Gc genotyping and GcMAF precursor activity. Anticancer Res 2005; 25(6A): 3689-95.
126. Yamamoto N, Homma S. Vitamin D3 binding protein (group-specific component) is a precursor for the macrophage-activating signal factor from lysophosphatidylcholine-treated lymphocytes. Proc Natl Acad Sci U S A 1991; 88(19): 8539-43.
127. Yamamoto N, Homma S, Millman I. Identification of the serum factor required for in vitro activation of macrophages. Role of vitamin D3-binding protein (group specific component, Gc) in lysophospholipid activation of mouse peritoneal macrophages. J Immunol 1991; 147(1): 273-80.
128. Yamamoto N, Naraparaju VR. A defect in inducible beta-galactosidase of B lymphocytes in the osteopetrotic (mi/mi) mouse. Immunology 1996; 88(4): 604-10.
129. Yamamoto N, Naraparaju VR. A defect in beta-galactosidase of B lymphocytes in the osteopetrotic (op/op) mouse. Immunol Lett 1996; 50(1-2): 35-40.
130. Schneider GB, Benis KA, Flay NW, Ireland RA, Popoff SN. Effects of vitamin D binding protein-macrophage activating factor (DBP-MAF) infusion on bone resorption in two osteopetrotic mutations. Bone 1995; 16(6): 657-62.
131. Swamy N, Ghosh S, Schneider GB, Ray R. Baculovirus-expressed vitamin D-binding protein-macrophage activating factor (DBP-maf) activates osteoclasts and binding of 25-hydroxyvitamin D(3) does not influence this activity. J Cell Biochem 2001; 81(3): 535-46.
132. Yamamoto N, Suyama H, Nakazato H, Yamamoto N, Koga Y. Immunotherapy of metastatic colorectal cancer with vitamin D-binding protein-derived macrophage-activating factor, GcMAF. Cancer Immunol Immunother 2008; 57(7): 1007-16.
133. Yamamoto N, Suyama H, Yamamoto N. Immunotherapy for Prostate Cancer with Gc Protein-Derived Macrophage-Activating Factor, GcMAF. Transl Oncol 2008; 1(2): 65-72.
134. Yamamoto N, Suyama H, Yamamoto N, Ushijima N. Immunotherapy of metastatic breast cancer patients with vitamin D-binding protein-derived macrophage activating factor (GcMAF). Int J Cancer 2008; 122(2): 461-7.
135. Gregory KJ, Zhao B, Bielenberg DR, et al. Vitamin D binding protein-macrophage activating factor directly inhibits proliferation, migration, and uPAR expression of prostate cancer cells. PLoS One 2010; 5(10): e13428.
136. Nonaka K, Onizuka S, Ishibashi H, et al. Vitamin D binding protein-macrophage activating factor inhibits HCC in SCID mice. J Surg Res 2012; 172(1): 116-22.
137. Pacini S, Punzi T, Morucci G, Gulisano M, Ruggiero M. Effects of Vitamin D-binding Protein-derived Macrophage-activating Factor on Human Breast Cancer Cells. Anticancer Res 2012; 32(1): 45-52.
138. Rehder DS, Nelson RW, Borges CR. Glycosylation status of vitamin D binding protein in cancer patients. Protein Sci 2009; 18(10): 2036-42.
139. Horne SL, Cockcroft DW, Dosman JA. Possible protective effect against chronic obstructive airways disease by the GC2 allele. Hum Hered 1990; 40(3): 173-6.
140. Schellenberg D, Pare PD, Weir TD, Spinelli JJ, Walker BA, Sandford AJ. Vitamin D binding protein variants and the risk of COPD. Am J Respir Crit Care Med 1998; 157(3 Pt 1): 957-61.
141. Wood AM, Bassford C, Webster D, et al. Vitamin D-binding protein contributes to COPD by activation of alveolar macrophages. Thorax 2011; 66(3): 205-10.
142. Ishii T, Keicho N, Teramoto S, et al. Association of Gc-globulin variation with susceptibility to COPD and diffuse panbronchiolitis. Eur Respir J 2001; 18(5): 753-7.
143. Ito I, Nagai S, Hoshino Y, et al. Risk and severity of COPD is associated with the group-specific component of serum globulin 1F allele. Chest 2004; 125(1): 63-70.
144. Dimeloe S, Hawrylowicz C. A direct role for vitamin D-binding protein in the pathogenesis of COPD? Thorax 2011; 66(3): 189-90.
145. Martineau AR, Leandro AC, Anderson ST, et al. Association between Gc genotype and susceptibility to TB is dependent on vitamin D status. Eur Respir J 2010; 35(5): 1106-12.
146. Weinstein SJ, Stolzenberg-Solomon RZ, Kopp W, Rager H, Virtamo J, Albanes D. Impact of Circulating Vitamin D Binding Protein Levels on the Association Between 25-Hydroxyvitamin D and Pancreatic Cancer Risk: A Nested Case-control Study. Cancer Res 2012; 72: 1190-98.
147. Bikle DD, Gee E, Halloran B, Haddad JG. Free 1, 25-dihydroxyvitamin D levels in serum from normal subjects, pregnant subjects, and subjects with liver disease. J Clin Invest 1984; 74(6): 1966-71.
148. Reese PP, Bloom RD, Feldman HI, et al. Changes in vitamin D binding protein and vitamin D concentrations associated with liver transplantation. Liver Int 2012; 32(2): 287-96.
149. Auwerx J, De Keyser L, Bouillon R, De Moor P. Decreased free 1, 25-dihydroxycholecalciferol index in patients with the nephrotic syndrome. Nephron 1986; 42(3): 231-5.
150. van Hoof HJ, de Sevaux RG, van Baelen H, et al. Relationship between free and total 1, 25-dihydroxyvitamin D in conditions of modified binding. Eur J Endocrinol 2001; 144(4): 391-6.
151. Bouillon R, Van Assche FA, Van Baelen H, Heyns W, De Moor P. Influence of the vitamin D-binding protein on the serum concentration of 1, 25-dihydroxyvitamin D3. Significance of the free 1, 25-dihydroxyvitamin D3 concentration. J Clin Invest 1981; 67(3): 589-96.
152. Ahn J, Yu K, Stolzenberg-Solomon R, et al. Genome-wide association study of circulating vitamin D levels. Hum Mol Genet 2010; 19(13): 2739-45.
153. Wang TJ, Zhang F, Richards JB, et al. Common genetic determinants of vitamin D insufficiency: a genome-wide association study. Lancet 2010; 376(9736): 180-8.
154. McGrath JJ, Saha S, Burne TH, Eyles DW. A systematic review of the association between common single nucleotide polymorphisms and 25-hydroxyvitamin D concentrations. J Steroid Biochem Mol Biol 2010; 121(1-2): 471-7.
155. Jones G. Pharmacokinetics of vitamin D toxicity. Am J Clin Nutr 2008; 88(2): 582S-586S.
156. Melamed ML, Michos ED, Post W, Astor B. 25-hydroxyvitamin D levels and the risk of mortality in the general population. Arch Intern Med 2008; 168(15): 1629-37.
157. McGrath JJ, Eyles DW, Pedersen CB, et al. Neonatal vitamin D status and risk of schizophrenia: a population-based case-control study. Arch Gen Psychiatry 2010; 67(9): 889-94.
158. Stolzenberg-Solomon RZ, Jacobs EJ, Arslan AA, et al. Circulating 25-hydroxyvitamin D and risk of pancreatic cancer: Cohort Consortium Vitamin D Pooling Project of Rarer Cancers. Am J Epidemiol 2010; 172(1): 81-93.
159. Vieth R. How to optimize vitamin D supplementation to prevent cancer, based on cellular adaptation and hydroxylase enzymology. Anticancer Res 2009; 29(9): 3675-84.
160. Faict D, De Moor P, Bouillon R, et al. Transcortin and vitamin D-binding protein levels in mouse serum. J Endocrinol 1986; 109(2): 141-7.
161. Abbas S, Linseisen J, Slanger T, et al. The Gc2 allele of the vitamin D binding protein is associated with a decreased postmenopausal breast cancer risk, independent of the vitamin D status. Cancer Epidemiol Biomarkers Prev 2008; 17(6): 1339-43.
162. Laufs J, Andrason H, Sigvaldason A, et al. Association of vitamin D binding protein variants with chronic mucus hypersecretion in Iceland. Am J Pharmacogenomics 2004; 4(1): 63-8.
163. Shen LH, Zhang XM, Su DJ, et al. Association of vitamin D binding protein variants with susceptibility to chronic obstructive pulmonary disease. J Int Med Res 2010; 38(3): 1093-8.
164. Lauridsen AL, Vestergaard P, Hermann AP, Moller HJ, Mosekilde L, Nexo E. Female premenopausal fracture risk is associated with gc phenotype. J Bone Miner Res 2004; 19(6): 875-81.
165. Eloranta JJ, Wenger C, Mwinyi J, et al. Association of a common vitamin D-binding protein polymorphism with inflammatory bowel disease. Pharmacogenet Genomics 2011; 21(9): 559-64.
166. Korytina GF, Akhmadishina LZ, Ianbaeva DG, Viktorova TV. Genotypes of vitamin-D-binding protein (DBP) in patients with chronic obstructive pulmonary disease and healthy population of Republic Bashkortostan. Mol Biol (Mosk) 2006; 40(2): 231-8.
167. Fang Y, van Meurs JB, Arp P, et al. Vitamin D binding protein genotype and osteoporosis. Calcif Tissue Int 2009; 85(2): 85-93.
168. Li F, Jiang L, Willis-Owen SA, Zhang Y, Gao J. Vitamin D binding protein variants associate with asthma susceptibility in the Chinese Han population. BMC Med Genet 2011; 12: 103.
169. Faserl K, Golderer G, Kremser L, et al. Polymorphism in vitamin D-binding protein as a genetic risk factor in the pathogenesis of endometriosis. J Clin Endocrinol Metab 2011; 96(1): E233-41.
170. Kurylowicz A, Ramos-Lopez E, Bednarczuk T, Badenhoop K. Vitamin D-binding protein (DBP) gene polymorphism is associated with Graves' disease and the vitamin D status in a Polish population study. Exp Clin Endocrinol Diabetes 2006; 114(6): 329-35.
171. Flohil SC, de Vries E, van Meurs JB, et al. Vitamin D-binding protein polymorphisms are not associated with development of (multiple) basal cell carcinomas. Exp Dermatol 2010; 19(12): 1103-5.
172. Ezura Y, Nakajima T, Kajita M, et al. Association of molecular variants, haplotypes, and linkage disequilibrium within the human vitamin D-binding protein (DBP) gene with postmenopausal bone mineral density. J Bone Miner Res 2003; 18(9): 1642-9.